stockportfolio.pro
Forte Biosciences, Inc. (FBRX)
Healthcare · Biotechnology · NasdaqCM
Forte Biosciences, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $49,000 | $41,000 | $18.04M | $36,000 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | $-33.48M | $-38.93M | $-48.95M | $-4.07M | $-46.49M | $-21.71M | $-13.88M | $-31.48M | $-35.48M | $-69.38M |
| Net margin | -68322.4% | -94948.8% | -271.4% | -11302.8% | — | — | — | — | — | — |
Source: Forte Biosciences, Inc. SEC filings (10-K). 11 years of history available in the interactive view.
Explore 11 years of Forte Biosciences, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track FBRX in your portfolio →
Forte Biosciences, Inc. financial history by metric
About Forte Biosciences, Inc.
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as celiac disease, vitiligo, alopecia areata, and type 1 diabetes. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Forte Biosciences, Inc. — frequently asked questions
What is Forte Biosciences, Inc.'s revenue?
Forte Biosciences, Inc. (FBRX) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Forte Biosciences, Inc. profitable?
No — FBRX reported a net loss of $-69.38M in fiscal 2025.
What is FBRX's P/E ratio?
Forte Biosciences, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Forte Biosciences, Inc. have?
As of fiscal year 2025, FBRX carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Forte Biosciences, Inc.'s market cap?
Forte Biosciences, Inc. (FBRX) has a market capitalization of about $368.41M, based on the latest data in our nightly-refreshed cache.
When does Forte Biosciences, Inc.'s fiscal year end?
FBRX's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Forte Biosciences, Inc.'s official SEC filings (10-K and 10-Q), covering 11 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.